Prevalence of Sarcopenic Obesity and its Association with Functionality, Lifestyle, Biomarkers and Morbidities in Older Adults: the FIBRA-RJ Study of Frailty in Older Brazilian Adults

Glaucia Cristina de Campos, Roberto Alves Lourenço, Claudia S. Lopes

OBJECTIVES: To assess the prevalence of sarcopenic obesity and its association with functionality, lifestyle, biomarkers, and morbidities in older adults.

METHODS: The study analyzed cross-sectional data from 270 older adults who participated in phase III of the Frailty in Brazilian Older People Study (Fragilidade em Idosos Brasileiros—Rio de Janeiro, FIBRA-RJ study—2013). They took part in a home interview surveying socioeconomic, demographic, lifestyle, morbidities, and functional data. Blood was collected for biochemical marker analysis and participants' body composition was determined by dual-energy X-ray absorptiometry. For women, the diagnosis of sarcopenic obesity was defined at a body fat percentage $\geq 38\%$ and appendicular skeletal muscle mass index (ASMMI) $<5.45$ kg/m$^2$. For men, a fat percentage $\geq 27\%$ and ASMMI $<7.26$ kg/m$^2$ was defined as sarcopenic obesity. Multivariate analysis was performed using a multinomial regression model (95% confidence intervals), with sarcopenic obesity as the outcome.

RESULTS: The prevalence of sarcopenic obesity was 29.3%. In the final fitted model, the variables that displayed statistically significant association with sarcopenic obesity were lower gait speed, self-reported medical diagnosis of arthrosis or arthritis, and high levels of glycemia.

CONCLUSION: The study showed a high prevalence of sarcopenic obesity in non-institutionalized older adults in Brazil. The finding that this condition was associated with modifiable risk factors may provide insights into measures directed at prevention and reduction of the risk of sarcopenic obesity in this population subgroup.

KEYWORDS: Cross-Sectional Study; Elderly; Obesity; Sarcopenic Obesity.

INTRODUCTION

The diagnosis of sarcopenic obesity (SO) considers the simultaneous presentation of high fat mass and low muscle mass; it represents the confluence between two body-composition phenotypes: sarcopenia and obesity. In recent years, obesity and sarcopenia have come to be considered as global epidemics, having a substantial impact on older adults’ quality of life, mainly through the synergistic effects of these two factors.

Globally, and in Brazil, the prevalence of SO in older adults has increased in recent years (1-7). However, due to the use of different diagnostic criteria and methods, the reported prevalence has varied considerably.

Studies using anthropometric measurements and electrical bioimpedance to diagnose SO have tended to find prevalence values ranging from 2% to 25% (8-11). Studies using dual-energy X-ray absorptiometry (DXA) have observed higher prevalence values, ranging from 2.75% to 84% (2,3,12-19). Baumgartner (17) was one of the pioneers in defining SO using DXA as a diagnostic method (20,21).

The DXA assessment of body composition is less likely to be influenced by body water content than other methods. Measurements obtained by this method has been considered as a reference standard in validation studies of methods and equations used to assess body composition. This method offers good validity and reliability and is a non-invasive technique for collecting information on various human body tissue types (22-24).

Prior studies have found an association between SO and functionality, sedentarism, biomarkers such as C-reactive protein (CRP), glucose, and albumin, and diabetes mellitus (18,20,25,26). In a study of 2,264 older adults in Korea, Ryu et al. (18) showed that engaging in moderate physical activity was inversely associated with SO.
More recently, there has been increasing interest in elucidating the relationship between biomarkers and SO (26,27). In several studies, biochemical markers, such as C-reactive protein (CRP) (26), glucose, and albumin (25,28), have been associated with SO. The association was usually two-way, but there was some evidence that high CRP and insulin resistance can predict SO (26). A high CRP level is a non-specific clinical marker of inflammation, and is associated with muscle catabolism (20,26).

SO is associated with increased morbidity, mortality, reduced quality of life, increased hospital admissions, and higher health costs (7,29). However, the related studies have used different criteria and methods, and, in Brazil, few studies used DXA (1,30-32) as a method for evaluating SO, and none have investigated its associated factors in the present study.

Accordingly, the objective of this study was to evaluate the prevalence of SO in older adults in Brazil, and to investigate its association with functionality, lifestyle, particular biomarkers, and physical morbidity.

## MATERIAL AND METHODS

### Study design and population

The methodology of the Frailty in Brazilian Older Adults study (Frailglide em Idosos Brasileiros, secção Rio de Janeiro, FIBRA-RJ), was described elsewhere (33). Briefly, this is a three-phase cohort study, whose sample population was sourced from the client database of a health care and social security foundation. In phase I, in 2009, the baseline sample was enrolled using the following inclusion criteria: being a client of the social security foundation for at least 1 year; being 65 years or older; and residing in one of the northern neighborhoods of Rio de Janeiro City, Brazil. The exclusion criteria were: having a Mini-Mental State Examination (MMSE) score of ≤13; having an active neuropsychiatric condition; having severe hearing or sight impairment that would prevent response to the questionnaire; having a limiting gait disturbance; or being a wheelchair user or bedbound. Participants were interviewed at their homes. The sampling plan was stratified by sex and age group. An inverse sampling strategy was applied to achieve a sample size representative of each stratum, making it unnecessary to increase the calculated sample size to offset the non-response rate (33). The first phase sample comprised 847 individuals.

The data analyzed in the present study were obtained from the phase III database recorded in 2013. From the phase I sample, 136 individuals were excluded due to death and 102 individuals for the following reasons: MMSE score of ≤13; institutionalization; wheelchair user or bedbound; pacemaker user; difficulty in walking; or severe cognitive changes reported by the family. After these exclusions, 609 individuals were eligible, and attempts were made to contact them to request participation. Of these, 64 could not be located, and 143 refused to take part. Thus, 402 older adults constituted the final sample; these individuals participated in home interviews, following the phase I protocol.

For blood tests and body composition evaluation, all 402 individuals were invited to visit the clinical analysis and nutritional evaluation laboratories of Rio de Janeiro State University (Universidade do Estado do Rio de Janeiro, UERJ). Transport was offered to those with difficulty in traveling from home. Three hundred individuals agreed to proceed with the study; the blood test was performed on 297 and the DXA examination on 270 (Figure 1).

### Measurements and variables

#### Body composition

Weight and height were measured for all participants while barefoot and wearing light clothing, using the methods described by Lohman et al. (34). Height was measured using a tape measure fixed to the wall and was recorded in millimeters, with no rounding. Weight was measured using portable digital scales (Plenna/Everest TIN-00110), with a capacity of 150 kg and accurate to 200 g, and was recorded to a tenth of a kilogram, with no rounding.

DXA was used to evaluate body composition (General Electric, model GE Lunar IDXA). Fat mass and lean mass were analyzed. The upper and lower limbs were isolated from the trunk and head by lines drawn by the software, which could then be manually adjusted with precision. Appendicular muscle mass was evaluated by means of the appendicular skeletal muscle mass index (ASMMI), obtained by adding lean mass, i.e., lean tissue (kg), from the arm and leg regions, and dividing by the square of the height (meters) (35).

#### Independent variable

SO was diagnosed by a combination of variables used to diagnose obesity and sarcopenia as measured by DXA. Elderly individuals were classified as obese by body fat percentage cut-off values (≥38% for women and ≥27% for men) (17,36), and as sarcopenic when the ASMMI was <7.26 kg/m² for men, and <5.45 kg/m² for women (36). Accordingly, women with both a fat percentage ≥38% and ASMMI <5.45 kg/m², and men with both a fat percentage ≥27% and ASMMI <7.26 kg/m², were defined as having SO (17,36).

In order to evaluate the dependent variable, SO, participants were categorized as eutrophic, non-sarcopenic obese, or sarcopenic obese.

#### Functional variables and physical morbidities

Gait speed was evaluated by measuring the time taken by the individual to walk 4.6 meters at their habitual pace. A chronometer was started at the moment the individual placed a foot on the starting mark and lifted the other off the ground. Individuals with gait speeds of 0.8 m/s or less were considered as displaying gait slowing (35).

Muscular strength was evaluated by taking three measurements at regular intervals of 1 minute using a hydraulic dynamometer (Jamar NC 701/42—North Coast, Rio de Janeiro, Brazil) in the dominant hand. The grip was adjusted according to the participant’s sex: position 2 for women and position 3 for men. The mean value of the three measurements was calculated and analyzed with adjustment for the individual’s sex and BMI. Individuals in the first performance quintile were considered to have low hand-grip strength (37).

Instrumental Activities of Daily Living (IADLs) were assessed using the Lawton scale (38), for seven day-to-day activities: using the telephone, shopping, leaving home
alone, preparing meals, performing domestic chores, managing finances, and taking medicines. Individuals needing help in any one activity or more were considered dependent.

Physical morbidities—diabetes mellitus and arthrosis/arthritis—were investigated by self-reporting in answer to the question: “Has a doctor ever told you that you have the following health problems: diabetes mellitus (Yes/No) and arthrosis/arthritis (Yes/No)?”

**Biomarkers.** CRP levels were considered abnormal at >0.5 mg/dl; albumin was considered low at <3.5 g/dl; and glycemia was considered high at >100 mg/dl. The participant’s blood samples were collected by trained technicians, by vacuum venipuncture, after a 12-hour fast. Participants abstained from physical exercise for 24 hours before collection, and from consuming alcohol in the 72 hours before collection.

**Lifestyle.** The lifestyle variables examined were tobacco use (current smoker/ever smoked and stopped/never smoked), walking for exercise (Yes/No), and consuming alcohol on a daily basis (Yes/No).

**Covariables.** The socioeconomic and demographic variables: age, sex, income, schooling, and race were included as covariables.

Age was recorded in years, in three age groups (65-74 years; 75-84 years; ≥85 years). Income source was described as retired, pensioners, and/or with other sources of income. Individual income from work, retirement benefit, or pension was recorded in minimum wages (MWs) at the time of interview and was categorized as 0-2 MWs; 2.1-5 MWs; and >5 MWs. Education was recorded in years and was categorized as illiterate, 1-5 years, 6-11 years, and ≥12 years. Race was categorized as white and Afro-descendent.

**Statistical analysis**
For descriptive analysis, absolute and relative frequencies were calculated for the categorical variables. To evaluate the dependent variable, individuals were categorized as
RESULTS

Subsequent multivariate analysis was performed by multinomial logistic model, which yielded crude and adjusted odds ratios (ORs) as measures of association, together with their respective 95% confidence intervals (95%CI). That model was used to identify associations of functional variables, morbidities, biochemical markers, and lifestyle with SO.

Independent variables that returned \( p < 0.20 \) in the bivariate analysis were included in the multivariate models. We evaluate the fit of the model using the deviance statistic and the pseudo-R of Nagelkerke. Statistical analysis was conducted using the statistical package SPSS for Windows, version 19.

Ethical considerations

The study followed the recommendations of Resolution 196/96 of the Ministry of Health’s National Health Council (Conselho Nacional de Saúde), and was approved by the National Research Ethics Committee (Comissão Nacional de Ética e Pesquisa, CONEP), in opinion No. 120.700/2012. All participants signed a declaration of free and informed consent.

This study examined 270, predominantly female, older adults, of mean age 77.5 years (SD=5.92). The prevalence of SO was 29.3% (n=78). Most participants were white, with an income ranging from 2.1 to 5 MW, and were in the 75-84 year age group. Almost half had 6-11 years’ education, while about one-third had more than 12 years’ education (Table 1).

Table 2 shows the prevalence of SO, by socioeconomic, demographic, lifestyle, morbidity, biochemical marker, and functional characteristics. The prevalence of SO was markedly higher among men than among women, and among white than among Afro-descendent individuals. Less than one-third of individuals with SO had 6-11 years’ education, while just more than one-third reported an income of >5 MW (Table 2).

The prevalence of SO among people with and without arthrosis/arthritis was significantly different, but was not different among those with and without DM, and was similar between those with arthrosis/arthritis and those with DM (\( p < 0.0001 \)) (Table 2).

Among the lifestyle variables, a high prevalence of SO was observed in older adults who had stopped smoking and who drank alcohol daily, but these findings lacked statistical significance. SO was also present in more than one-quarter of older adults who did not walk for exercise, but this was not statistically significant (Table 2).

Analysis of the biomarkers showed that about one-fifth of older adults with SO also had hypoalbuminemia, about one-third had hyperglycemia, and about one-quarter had elevated CRP levels (Table 2).

In terms of functional variables, among individuals with SO, more than 30% had lower gait speed, more than one-third had reduced hand-grip strength, and about one-third were dependent according to the IADLs (Table 2).

Table 3 shows the means and standard deviations for body composition characteristics, by presence of obesity and SO. Individuals with SO had higher mean fat percentage values than eutrophic individuals (\( p < 0.001 \)). The percentage of fat in obese individuals was exceeded when wishing with sarcopenic obsession. Individuals with SO also had lower mean muscular mass index values than obese individuals (\( p < 0.001 \)).

Table 4 states the crude and adjusted ORs for the associations between the independent variables (functional, morbidity, lifestyle, and biomarker) and SO. The crude analyses showed that lower gait speed, daily consumption of alcohol, and hyperglycemia displayed significant associations with SO. In the final model, adjusted by the demographic and socioeconomic variables, lower gait speed, arthrosis/arthritis, and hyperglycemia were significantly associated with SO.

In Table 5, the crude and adjusted ORs for the associations between the independent variables and obesity are stated. In the final model, adjusted by the demographic and socioeconomic variables, lower gait speed, arthrosis/arthritis, and hyperglycemia were significantly associated with obesity.

DISCUSSION

This study found a high prevalence of SO and obesity among older adults in Brazil. These results corroborate other Brazilian and international studies (1,16,18,26,27,30). The prevalence of SO in Brazilian studies have ranged from 19.6% to 34.2% (30,32,39,40). Globally, studies of non-institutionalized older adults have reported an SO prevalence ranging from 2.1% to 94% (14,15,19,40,41). In Brazil, a cross-sectional study of 272 older women by Silva et al. (30) found a prevalence of SO of 34.2%, based on DXA evaluations (30).
A cross-sectional study of 306 older adults in Spain found a prevalence of SO of 25% (10). The present study found a higher prevalence of SO among men (65.3%) than among women (34.6%). This was a similar trend to that found by Batsis et al. (41), in a cross-sectional study in the United States by the National Health and Nutrition Examination Survey III—1999-2004. In a sub-sample of 4,984 non-institutionalized older adults of both sexes, aged 60 years or more, using cut-off points proposed by the Foundation for the National Institutes of Health, they observed a prevalence of SO, as evaluated by appendicular skeletal muscle mass, of 27.8% in men and 19.3% in women. However, contradictory results were observed in the study (19) using data from the National Health and Nutrition Examination Survey (1999-2004) for 4,984 older adults in the United States, using different definitions from six studies (4,5,42-45) and different diagnostic criteria for SO. In that study, they found widely differing prevalence values for SO, which were often higher among women, ranging from 3.6% to 94.0%, while among the men the values varied from 4.4% to 84.0%.

Thus, the prevalence of SO is not yet clearly established and can vary by a factor of as much as 26, mainly because of

### Table 2 - Prevalence of sarcopenic obesity, by sociodemographic and economic characteristics, lifestyle, morbidities, and biochemical and functional markers (FIBRA-RJ-2013).

| Variables            | Eutrophy | Obesity | Sarcopenic obesity | N (%)   | p-value |
|----------------------|----------|---------|--------------------|---------|---------|
| **Sex**              |          |         |                    |         |         |
| Female               | 46       | 25      | 111                | 60.3    | 27      | 14.7 | 0.0001 |
| Male                 | 24       | 29.60   | 6                  | 7.4     | 51      | 63.6 | 0.021  |
| **Ethnicity**        |          |         |                    |         |         |
| White                | 39       | 23.35   | 69                 | 41.3    | 59      | 35.33 | 0.021 |
| Afro-descendent      | 31       | 31.63   | 48                 | 48.98   | 19      | 19.39 |         |
| **Income bracket (*MW)** |        |         |                    |         |         |
| 0-2                  | 8        | 16.67   | 22                 | 45.83   | 18      | 37.50 | 0.010  |
| > 2.1-5              | 30       | 25.86   | 60                 | 51.72   | 26      | 22.41 |         |
| > 5                  | 29       | 33.33   | 26                 | 29.89   | 32      | 36.78 | 0.609  |
| **Age group (years)**|          |         |                    |         |         |
| 65-74                | 23       | 23.00   | 50                 | 50.00   | 27      | 27.00 | 0.060  |
| 75-84                | 34       | 27.42   | 52                 | 41.94   | 38      | 30.65 |         |
| > 85                 | 13       | 31.71   | 15                 | 36.59   | 13      | 31.71 |         |
| **Schooling (years)**|          |         |                    |         |         |
| Illiterate           | 0        | 0.00    | 1                  | 100.00  | 0       | 0.00  | 0.254  |
| 1-5                  | 14       | 28.00   | 26                 | 52.00   | 10      | 20.00 |         |
| 6-11                 | 29       | 25.37   | 59                 | 47.58   | 36      | 29.03 |         |
| > 12                 | 27       | 30.00   | 31                 | 34.44   | 32      | 35.56 |         |
| **Diabetes Mellitus**|          |         |                    |         |         |
| Yes                  | 17       | 25.00   | 36                 | 52.94   | 15      | 22.06 | 0.202  |
| No                   | 53       | 27.04   | 81                 | 41.33   | 62      | 31.63 |         |
| **Arthrosis/Arthritis**|        |         |                    |         |         |
| Yes                  | 26       | 19.7    | 76                 | 57.6    | 30      | 22.7  | 0.000  |
| No                   | 44       | 33.1    | 41                 | 30.8    | 48      | 36.1  |         |
| **Tobacco use**      |          |         |                    |         |         |
| Yes                  | 4        | 33.33   | 4                  | 33.33   | 4       | 33.33 | 0.020  |
| No                   | 40       | 25.3    | 82                 | 51.9    | 36      | 22.8  |         |
| Smoked and stopped   | 26       | 27.4    | 31                 | 32.6    | 38      | 40.0  |         |
| **Daily consumption of alcohol** |        |         |                    |         |         |
| Yes                  | 7        | 18.92   | 12                 | 32.43   | 18      | 48.65 | 0.022  |
| No                   | 63       | 27.63   | 105                | 46.05   | 60      | 26.32 |         |
| **Walking for exercise** |        |         |                    |         |         |
| Yes                  | 19       | 30.16   | 19                 | 30.16   | 25      | 39.68 | 0.029  |
| No                   | 51       | 25.25   | 98                 | 48.51   | 53      | 26.24 |         |
| **Albumin**          |          |         |                    |         |         |
| Normal               | 69       | 28.5    | 101                | 41.7    | 72      | 29.8  | 0.007  |
| Deficit              | 1        | 4.8     | 16                 | 76.2    | 4       | 19.0  |         |
| **C-reactive protein** |        |         |                    |         |         |
| Normal               | 63       | 28.6    | 91                 | 41.4    | 66      | 30.0  | 0.061  |
| High                 | 7        | 16.3    | 26                 | 60.5    | 10      | 23.3  |         |
| **Glycemia**         |          |         |                    |         |         |
| Normal               | 48       | 33.8    | 57                 | 40.1    | 37      | 26.4  | 0.017  |
| High                 | 22       | 18.2    | 60                 | 49.6    | 39      | 32.2  |         |
| **Gait speed**       |          |         |                    |         |         |
| ≤ 0.8m/s            | 20       | 17.4    | 62                 | 53.9    | 33      | 28.7  | 0.004  |
| > 0.8m/s            | 50       | 33.6    | 54                 | 36.2    | 45      | 30.2  |         |
| **Hand grip**        |          |         |                    |         |         |
| Low                  | 15       | 21.7    | 29                 | 42      | 25      | 36.2  | 0.320  |
| Normal               | 55       | 28.1    | 88                 | 44.9    | 53      | 27.0  |         |
| **IADL**             |          |         |                    |         |         |
| Independent          | 47       | 27.6    | 76                 | 44.7    | 47      | 27.6  | 0.820  |
| Dependent            | 23       | 24.2    | 41                 | 43.2    | 31      | 32.6  |         |

* MW—Minimum Wage; **IADL—Instrumental Activities of Daily Living.

### Table 3 - Measures and standard deviation of body composition characteristics, by body composition phenotypes and anthropometry (FIBRA-RJ-2013).

| Body Composition and Anthropometry | Obesity | Sarcopenic Obesity | Total |
|-----------------------------------|---------|--------------------|-------|
| N     | Mean  | SD    | N     | Mean  | SD    | N     | Mean  | SD    |
| Fat Percentage (%)                | 117     | 44.9  | 3.7   | 78    | 35.6  | 4.5   | 265   | 38.5  | 7.5   | < 0.001 |
| ASMMI (Kg/m²)*                    | 117     | 7.5   | 1.7   | 78    | 5.1   | 0.8   | 265   | 5.9   | 2.0   | < 0.001 |
| Weight (Kg)                       | 117     | 73.6  | 12.5  | 78    | 67.4  | 12.6  | 265   | 68.0  | 13.4  | < 0.001 |
| Waist Circumference (cm)           | 117     | 102.5 | 10.5  | 78    | 96.8  | 8.9   | 265   | 96.6  | 12.0  | < 0.001 |

*ASMMI—Appendicular Skeletal Muscle Mass Index.
the use of different evaluation methods, criteria, and cut-off points applied to determine muscle mass and fat mass (19). This variability underlines the need to establish diagnostic criteria and cut-off points in order to build a consensus in the scientific literature (23). In addition, ethnic differences may influence the prevalence of SO, given that oriental populations have less muscle mass and fat mass than western populations (46).

Moon et al. (6), in a study of 1,583 older adults in Korea between 2008 and 2010, found a lower SO prevalence: 7.8% for men and 9.6% for women. Moreover, Kim et al. (26) analyzed baseline data for 493 older adults from the Korean Sarcopenic Obesity Study (KSOS) and found a prevalence of SO of 17.8% for men and 24.9% for women.

It has been suggested that obesity can lead to sarcopenia, and vice versa (46-48). The underlying mechanism is related to the production of substances in fatty tissue, such as tumor necrosis factor and leptin, which influence insulin resistance, reduction of energy metabolism, and secretion of growth hormone and proinflammatory cytokines, leading to progressive muscle mass loss and body fat increase, particularly by fatty infiltration of muscle (47). Muscle with high levels of infiltrated fat may be more inflamed than fat-free muscle, suggesting a connection between fat mass gain, and muscles with increased triglycerides and inflammation (47,49). Increased adiposity leads to chronic subclinical inflammation, which fosters muscle catabolism and can lead to sarcopenia (50).

Thus, the results of this study, which showed a high prevalence of obesity (44.2%) among non-institutionalized older adults, can serve as an alert to the greater risk of such older adults developing SO in the near future. The prevalence of SO and obesity is probably associated with the specific characteristics of our sample, which included older individuals and mostly women. Indeed, in other studies, the proportion of SO and obesity increased with age, most likely due to hormone-related body composition changes, reaching higher values in individuals over 75 years of age.

The results of this study confirm the associations of SO with gait speed, arthrosis, and diabetes mellitus, as reported in international studies (5,51). Lower gait speed is an important indicator of functional impairment in older adults, and this study found that older adults with reduced gait speed were twice as likely to display SO. A study by Chang et al. (9), in Taiwan examined data for 2,629 older adults from the Sarcopenia and Translational Ageing Research in Taiwan (START) survey, to evaluate the association between functionality and body composition. They found an association between lower gait speed and SO (p < 0.005). Moreira et al. (52), in a cross-sectional study of 491 participants in Parnamirim, Brazil, observed that variables relating to physical (functional) performance displayed statistically significant

| Table 4 - Crude and adjusted odds ratios (OR) and respective 95% confidence intervals (95%CI) for the association between sarcopenic obesity and functional variables and morbidities, lifestyle and biomarkers (FIBRA-RJ -2013). |
|-----------------|-----------------|-----------------|-----------------|-----------------|
| **Variables**   | **OR (95%CI)**  | **Model 1 Adjusted OR (95%CI)** | **Model 2 Adjusted OR (95%CI)** | **Model 3 Final Model Adjusted OR (95%CI)** |
| Gait speed      |                 |                 |                 |                 |
| >0.8 m/s        | 1               | 1               | 1               | 1               |
| <0.8 m/s        | 1.83 (0.92-3.64)| 2.01 (0.94-4.32)| 2.43 (1.09-5.41)|                 |
| Arthrosis       |                 |                 |                 |                 |
| No              | 1               | 1               | 1               | 1               |
| Yes             | 1.05 (0.54-2.05)| 2.05 (0.92-4.53)| 2.43 (1.05-5.63)|                 |
| Diabetes mellitus|               |                 |                 |                 |
| No              | 1               | 1               | 1               | 1               |
| Yes             | 0.75 (0.34-1.65)| 0.69 (0.29-1.67)| 0.52 (0.19-1.37)|                 |
| Smoking         |                 |                 |                 |                 |
| Never smoked    | 1               | 1               | 1               | 1               |
| Smoker          | 1.11 (0.25-4.77)| 0.67 (0.13-3.51)| 0.23 (0.03-1.75)|                 |
| Smoked and stopped| 1.62 (0.82-3.18)| 0.94 (0.43-2.08)| 0.75 (0.31-1.76)|                 |
| Daily drinker   |                 |                 |                 |                 |
| No              | 1               | 1               | 1               | 1               |
| Yes             | 2.70 (1.05-6.92)| 2.29 (0.81-6.46)| 2.63 (0.84-8.20)|                 |
| Walks           |                 |                 |                 |                 |
| No              | 0.79 (0.38-1.60)| 0.94 (0.42-2.09)| 0.86 (0.36-2.02)|                 |
| Yes             |                 |                 |                 |                 |
| Albumin         |                 |                 |                 |                 |
| Normal          | 1               | 1               | 1               | 1               |
| Deficit         | 3.83 (0.41-35.15)| 7.24 (0.72-72.85)| 5.70 (0.54-59.89)|                 |
| C-Reactive Protein|              |                 |                 |                 |
| Normal          | 1               | 1               | 1               | 1               |
| High            | 1.36 (0.48-3.80)| 1.38 (0.45-4.19)| 1.22 (0.37-4.02)|                 |
| Glycemia        |                 |                 |                 |                 |
| Normal          | 1               | 1               | 1               | 1               |
| High            | 2.30 (1.17-4.52)| 2.15 (1.02-4.55)| 3.14 (1.34-7.32)|                 |

Model 1 — Block of functional variables and morbidities (gait speed, arthrosis and diabetes mellitus) + adjusted for sociodemographic and economic variables (sex, income bracket and ethnicity).
Model 2 — Block of lifestyle variables (tobacco use, daily consumption of alcohol and walking for exercise) + adjusted for sociodemographic and economic variables.
Model 3 — Block of biochemical marker variables (glycaemia, albumin and C-reactive protein) + adjusted for sociodemographic and economic variables.
Model 4 — Final; Functional variables and morbidities, lifestyle, biochemical markers + adjusted for sociodemographic and economic variables.
association with SO, although there was no statistical significance to the association between gait speed and SO. This vicious cycle of functional incapacity and slower gait leads to a reduction in overall energy expenditure, reduced muscle mass, and increased fat mass in older adults.

Our findings in relation to elevated glycaemia were in agreement with the findings of the study in Korea by Hwang et al. (51), which examined data from the Fourth Korea National Health and Nutrition Examination Survey (2009), a population survey of 2,221 older adults. They found that older adults with hyperglycemia had higher odds of developing SO. Santos et al. (1), in a cross-sectional study in Brazil, examined 149 older women and found a positive correlation between glucose levels and SO ($p < 0.05$).

It remains unclear whether the presence of arthrosis/arthritis precedes SO or whether individuals with SO are at higher risk of developing arthritis/arthrosis. The possibility of bidirectionality between such events should not be discarded as it is quite plausible. However, we found no other study that has evaluated the role of arthrosis/arthrosis in the development of SO. Tyrovolas et al. (8) analyzed data from the Collaborative Research on Ageing in Europe (COURAGE) Survey and the World Health Organization Study on Global Ageing (SAGE), which comprised 18,363 older adults from several different geographical regions of the world, between 2007 and 2012. They observed that older adults with a chronic disease were 1.8 times more likely to develop SO.

This study had some limitations. Its cross-sectional design did not enable temporal or causal associations to be shown, leading to the possibility of reverse causation among the findings. This possibility cannot be excluded, given the bidirectionality of the phenomena studied. Another limitation involved the use of walking as physical exercise to assess the physical activity of the participants. This assessment is insufficient to assess the set of physical activities that are performed, and thus may have led to underestimation of this parameter. Additionally, there may have been information bias resulting from the self-reported physical morbidity data. The scarcity of studies and the great variability of diagnostic methods and criteria for SO placed limitations on data comparability. Moreover, the FIBRA-RJ study involves a closed cohort. This fact prevented the sample from being recomposed after losses occurred during the follow-up and exclusions during data collection. Despite these limitations, the specificities of the FIBRA-RJ sample has the advantage in terms of providing knowledge about the body composition phenotypes present in the elderly population.

To the best of our knowledge, no previous study had evaluated the prevalence of SO and its associations with functionality, lifestyle, biomarkers, and physical morbidity in Brazil, using the DXA method. Data quality was assured by

### Table 5 - Crude and adjusted odds ratios (OR) and respective 95% confidence intervals (95% CI) for the association between obesity and functional variables and morbidities, lifestyle and biomarkers (FIBRA-RJ -2013).

| Variables               | Obesity | Model 1 | Model 2 | Model 3 | Final Model |
|-------------------------|---------|---------|---------|---------|-------------|
|                         | OR (95%CI) | Adjusted OR (95%CI) | Adjusted OR (95%CI) | Adjusted OR (95%CI) | Adjusted OR (95%CI) |
| Gait speed              |          |         |         |         |             |
| >0.8 m/s                | 1        | 1       | 1       | 1       | 1           |
| ≤0.8 m/s                | 2.87 (1.52-5.44) | 2.01 (0.94-4.32) | 3.12 (1.45-6.67) |         |
| Arthrosis               |          |         |         |         |             |
| No                      | 1        | 1       | 1       | 1       | 1           |
| Yes                     | 3.13 (1.69-5.80) | 2.05 (0.92-4.53) | 2.54 (1.20-5.39) |         |
| Diabetes mellitus       |          |         |         |         |             |
| No                      | 1        | 1       | 1       | 1       | 1           |
| Yes                     | 1.38 (0.70-2.71) | 0.69 (0.29-1.67) | 1.09 (0.42-2.81) |         |
| Smoking                 |          |         |         |         |             |
| Never smoked            | 1        | 1       | 1       | 1       | 1           |
| Smoker                  | 0.48 (0.11-2.05) | 0.40 (0.08-1.86) | 0.33 (0.06-1.73) |         |
| Smoked and stopped      | 0.58 (0.30-1.10) | 0.90 (0.42-1.91) | 0.80 (0.35-1.83) |         |
| Daily drinker           |          |         |         |         |             |
| No                      | 1        | 1       | 1       | 1       | 1           |
| Yes                     | 1.02 (0.38-2.74) | 2.36 (0.75-7.43) | 2.98 (0.89-9.97) |         |
| Walks                   |          |         |         |         |             |
| Yes                     | 1        | 1       | 1       | 1       | 1           |
| No                      | 1.92 (0.93-3.94) | 1.36 (0.60-3.10) | 1.16 (0.48-2.78) |         |
| Albumin                 |          |         |         |         |             |
| Normal                  | 1        | 1       | 1       | 1       | 1           |
| Deficit                 | 10.93 (1.41-84.34) | 8.55 (1.05-69.35) | 6.23 (0.72-53.74) |         |
| C-Reactive Protein      |          |         |         |         |             |
| Normal                  | 1        | 1       | 1       | 1       | 1           |
| High                    | 2.57 (1.05-6.28) | 1.71 (0.64-4.58) | 1.76 (0.63-4.93) |         |
| Glycemia                |          |         |         |         |             |
| Normal                  | 1        | 1       | 1       | 1       | 1           |
| High                    | 2.29 (1.23-4.27) | 2.70 (1.32-5.55) | 3.09 (1.33-7.14) |         |

Model 1—Block of functional variables and morbidities (gait speed, arthrosis and diabetes mellitus) + adjusted for sociodemographic and economic variables (sex, income bracket and ethnicity).

Model 2—Block of lifestyle variables (tobacco use, daily consumption of alcohol and walking for exercise) + adjusted for sociodemographic and economic variables.

Model 3—Block of biochemical marker variables (glycaemia, albumin and C-reactive protein) + adjusted for sociodemographic and economic variables.

Model 4—Final; Functional variables and morbidities, lifestyle, biochemical markers + adjusted for sociodemographic and economic variables.
team training, data quality supervision and control immediately upon completion of the data collection protocols, and prompt correction of any errors. Lastly, evaluation of body composition by the DXA method, which is considered to be a reference method, provided greater precision and validity to the study findings.

■ CONCLUSION

In summary, this study revealed a high prevalence of obesity and SO among older adults in Brazil. The high prevalence of both these two body composition phenotypes are cause for concern, because obese older adults can become sarcopenic obese. The finding that slower gait, hyperglycemia, and artherosclerosis are associated with the presence of SO underscores the possibility that early intervention and prevention of these modifiable risk factors can assist in preventing obesity and SO in older adults.

Despite limited data comparability due to cultural and racial differences, and diversity in cut-off points and diagnostic criteria, the results of various different studies reinforce the association between slower gait speed, hyperglycemia, and SO in older adults. To improve research in this field and ensure better data comparability, it is of prime importance that consensus on the diagnosis of SO be established.

■ ACKNOWLEDGMENTS

de Campos GC et al. Sarcopenic obesity in Brazilian elderly analysis and manuscript and approval of the data collection, analysis, interpretation of data and preparation of the The Frailty in Brazilian Older Adults study (Estudo da Fragilidade em comissionado by the DXA method, which is considered to be a reference method, provided greater precision and validity to the study findings.

■ CONCLUSION

In summary, this study revealed a high prevalence of obesity and SO among older adults in Brazil. The high prevalence of both these two body composition phenotypes are cause for concern, because obese older adults can become sarcopenic obese. The finding that slower gait, hyperglycemia, and artherosclerosis are associated with the presence of SO underscores the possibility that early intervention and prevention of these modifiable risk factors can assist in preventing obesity and SO in older adults.

Despite limited data comparability due to cultural and racial differences, and diversity in cut-off points and diagnostic criteria, the results of various different studies reinforce the association between slower gait speed, hyperglycemia, and SO in older adults. To improve research in this field and ensure better data comparability, it is of prime importance that consensus on the diagnosis of SO be established.

■ ACKNOWLEDGMENTS

de Campos GC et al. Sarcopenic obesity in Brazilian elderly analysis and manuscript and approval of the data collection, analysis, interpretation of data and preparation of the The Frailty in Brazilian Older Adults study (Estudo da Fragilidade em comissionado by the DXA method, which is considered to be a reference method, provided greater precision and validity to the study findings.

■ CONCLUSION

In summary, this study revealed a high prevalence of obesity and SO among older adults in Brazil. The high prevalence of both these two body composition phenotypes are cause for concern, because obese older adults can become sarcopenic obese. The finding that slower gait, hyperglycemia, and artherosclerosis are associated with the presence of SO underscores the possibility that early intervention and prevention of these modifiable risk factors can assist in preventing obesity and SO in older adults.

Despite limited data comparability due to cultural and racial differences, and diversity in cut-off points and diagnostic criteria, the results of various different studies reinforce the association between slower gait speed, hyperglycemia, and SO in older adults. To improve research in this field and ensure better data comparability, it is of prime importance that consensus on the diagnosis of SO be established.

■ ACKNOWLEDGMENTS

de Campos GC et al. Sarcopenic obesity in Brazilian elderly analysis and manuscript and approval of the data collection, analysis, interpretation of data and preparation of the The Frailty in Brazilian Older Adults study (Estudo da Fragilidade em comissionado by the DXA method, which is considered to be a reference method, provided greater precision and validity to the study findings.
28. Hara N, Iwasa M, Sugimoto R, Mifoji-Moroka R, Yoshikawa K, Terasaka E, et al. Sarcopenia and Sarcopenic Obesity Are Prognostic Factors for Overall Survival in Patients with Cirrhosis. Intern Med. 2016;55(8):863-70. https://doi.org/10.1038/oby.2016.165

29. Janssen I, Shepard DS, Katzmarzyk PT, Roubenoff R. The healthcare costs of sarcopenia in the United States. J Am Geriatr Soc. 2004;52(1):80-5. https://doi.org/10.1046/j.1532-5415.2004.52014.x

30. Silva AO, Karmikowski MG, Funghetto SS, Stival MM, Lima RM, de Souza JC, et al. Association of body composition with sarcopenic obesity in elderly women. Int J Gene. 2013;6:25-9. https://doi.org/10.2147/IJGMS.S63279

31. Dutra MT. Associação entre sarcopenia e obesidade sarcópnica com variáveis inflamatórias em mulheres idosas. 2013.

32. Neto LS, Karnikowiski MG, Tavares AB, Lima RM. Associação entre sarcopenia, obesidade sarcópnica e força muscular com variáveis relacionadas de qualidade de vida em idosas. Rev. bras. fisioter. 2012;16(5):360-7.

33. Lourenço RA, Sanchez MA, Moreira VG, Ribeiro PC, Perez M, Campos GC, et al. Fragilidade em Idosos Brasileiros-FIBRA-RJ: metodologia de pesquisa dos estudos de fragilidade, distúrbios cognitivos e sarcopenia. Revista HUPE. 2015;14(4).

34. Loveman TG, Roche AF. Anthropometric standardization reference manual. Human kinetics books. 1988.

35. Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, et al. Sarcopenia: European consensus on definition and diagnosis. Report of the European Working Group on Sarcopenia in Older People. Age Ageing. 2010;39(4):412-23. https://doi.org/10.1093/ageing/afq034

36. Baumgartner RN, Wayne SJ, Waters DL, Janssen I, Gallagher D, Morley JE. Sarcopenic obesity predicts instrumental activities of daily living disability in the elderly. Obes Res. 2004;12(12):1995-2004. https://doi.org/10.1038/oby.2004.250

37. Moreira VG, Lourenço RA. Prevalence and factors associated with frailty in an older population from the city of Rio de Janeiro, Brazil: the FIBRA-RJ Study. Clinics. 2013;68(7):979-85. https://doi.org/10.6061/clinics/2013(07)15

38. Lawton MB, Brody EM. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist. 1969;9(3):179-86. https://doi.org/10.1093/geront/9.3_Part_1.179

39. Oliveira RJ, Bottaro M, Júnior JT, Farinatti PT, Bezerra LA, Lima RM. Identification of sarcopenic obesity in postmenopausal women: a cutoff proposal. Braz J Med Biol Res. 2011;44(11):1171-6. https://doi.org/10.1590/S0100-879X2011007500135

40. Gadilha AB, Dutra MT, de Oliveira RJ, Safons MP, Lima RM. Association among strength, sarcopenia and sarcopenic obesity with functional performance in older women. Assocociacao entre forca, sarcopenia e obesidade sarcopênica com o desempenho funcional de idosas. Morbidity. 2014; 10(3):31-40. https://doi.org/10.6063/morbidade.10.3.2775

41. Batsis JA, Mackenzie TA, Lopez-Jimenez F, Bartels SJ. Sarcopenia, sarcopenic obesity, and functional impairments in older adults: National Health and Nutrition Examination Surveys 1999-2004, Nutr Res. 2015; 35(12):1031-9. https://doi.org/10.1016/j.nutres.2015.09.003

42. Baumgartner RN, Koehler KM, Gallagher D, Romero L, Heymsfield SB, Ross RR, et al. Epidemiology of sarcopenia among the elderly in New Mexico. Am J Epidemiol. 1998;147(8):755-63. https://doi.org/10.1093/oxfordjournals.aje.a009520

43. Davison KK, Ford ES, Cogswell ME, Dietz WH. Percentage of body fat and body mass index are associated with mobility limitations in people aged 70 and older from NHANES III, J Am Geriatr Soc. 2002;50(11):1802-9. https://doi.org/10.1046/j.1532-5415.2002.500508.x

44. Zoico E, Di Francesco V, Guralnik JM, Mazzali G, Bortolani A, Guerriento S, et al. Physical disability and muscular strength in relation to obesity and different body composition indexes in a sample of healthy elderly women. Int J Obes Relat Metab Disord. 2004;28(2):234-41. https://doi.org/10.1038/sj.ijo.0802552

45. Kim TN, Yang SJ, Yoo HJ, Lim KJ, Kang HJ, Song W, et al. Prevalence of sarcopenia and sarcopenic obesity in Korean adults: the Korean sarcopenic obesity study. Int J Obes. 2009;33(8):885-92. https://doi.org/10.1038/j.ijo.2009.130

46. Kim TN, Park MS, Ryu JY, Choi HY, Hong HC, Yoo HJ, et al. Impact of visceral fat on skeletal muscle mass and vice versa in a prospective cohort study: the Korean Sarcopenic Obesity Study (KSOS). PLoS One. 2014; 9(12):e115407. https://doi.org/10.1371/journal.pone.0115407

47. Zamboni M, Mazzali G, Fantin F, Rossi A, Di Francesco V. Sarcopenic obesity: a new category of obesity in the elderly. Nutr Metab Cardiovasc Dis. 2008;18(5):388-95. https://doi.org/10.1016/j.numecd.2007.10.002

48. Roubenoff R, Hughes VA. Sarcopenia: current concepts. J Gerontol A Biol Sci Med Sci. 2000;55(12):M716-24. https://doi.org/10.1093/gerona/55.12.M716

49. Sakuma K, Yamaguchi A. Sarcopenic obesity and endocurial adaptation with age. Int J Endocrinol. 2013;2013:204164. https://doi.org/10.1155/2013/204164

50. Cauley JA, An Overview of Sarcopenic Obesity. J Clin Densitom. 2015; 18(4):499-505. https://doi.org/10.1016/j.jocd.2015.04.013

51. Hwang B, Lim JY, Lee J, Choi NK, Ahn YO, Park BJ. Prevalence rate and different body composition indexes in a sample of healthy elderly women. Int J Obes Relat Metab Disord. 2004;28(2):234-41. https://doi.org/10.1038/sj.ijo.0802552

52. Moreira MA, Zunzunegui MV, Vafaei A, da Câmara SM, Oliveira TS, Maciel AC. Sarcopenic obesity and physical performance in middle aged women: a cross-sectional study in Northeast Brazil. BMC Public Health. 2016;16:43. https://doi.org/10.1186/s12889-015-2667-4